Anti-Ebola MVA Vaccine Produced on Avian AGE1.CR® Cell Line in Clinical Trials

News   Jun 03, 2015

 
Anti-Ebola MVA Vaccine Produced on Avian AGE1.CR® Cell Line in Clinical Trials
 
 
 

RELATED ARTICLES

New Rare Antibody Isolation Strategy

News

A strategy for rapidly isolating rare, naturally occurring antibodies is reported this week. The strategy could aid in developing biological therapeutics and vaccines in the future.

READ MORE

Synthetic Horsepox Virus Could Lead to More Effective Smallpox Vaccine

News

University of Alberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox.

READ MORE

Radical New Approach to Vaccine Development Could Help Reduce Illness From Flu

News

More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help lower that figure for future flu seasons.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE